VYNE Therapeutics (VYNE)
Develops BET inhibitor therapies for inflammatory and immune-mediated diseases.
Something off on this page? Send us feedback.
VYNE is a clinical-stage biotech developing BET inhibitor drug candidates for inflammatory and immune-mediated diseases. Its pipeline centers on oral VYN202 while repibresib gel is being sought for external development.
VYNE Therapeutics is a US clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory and immune-mediated diseases. Its work is organized around the InhiBET platform, a small-molecule BET inhibitor library licensed from Tay Therapeutics, with two named programs: VYN202 and repibresib. VYN202 is an oral BD2-selective candidate being advanced after early clinical work in plaque psoriasis and additional toxicology work tied to a partial FDA hold in male subjects.
Repibresib, formerly VYN201, is a locally administered pan-BD BET inhibitor gel for nonsegmental vitiligo; after its study missed the main goal, VYNE is seeking an external development partner. A pending merger with Yarrow Bioscience would shift the public company toward Yarrow's thyroid autoimmunity program, so VYNE's legacy pipeline depends on partner, license, transfer, or divestiture decisions before closing.
Company facts
Target rangeAs of Aug 24, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Jul 30, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $29.0K · Total debt $0 · Total assets $30.2K · Shareholders' equity $27.8K
- Revenue
- $570.0K
- Operating income
- −$29.7M
- Net income
- −$26.5M
Last raised to $0.4024 from $0.38 split-adjusted in Jul 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 24, 2026 | Jul 22 | $0.4024 | raised from $0.38 split-adjusted | |
| Jul 22, 2026 | Jul 22 | Jul 23 | $0.38 |
| Institutions42 holders · as of Mar 31, 2026 | ≥ 9.86% | 263.2K shares | |
| Strategic holders1 holder · as of Jul 30, 2026 | 9.97% | 266.3K shares | |
| Otherremainder | ≤ 80.17% | 2.14M shares |
2.67M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.67M in the company's Sep 3, 2026 report, 667.7K elsewhere); stakes use the report.
Institutional filings for YARW (100% of the company) are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
venBio Global Strategic Fund V, L.P.Institution | 10.46% | 279,340 | 13Gfiled Aug 14, 2026 ↗ |
Logos Global Management LPInstitution | 10.36% | 276,704 | 13Gfiled Aug 4, 2026 ↗ |
Perceptive Advisors LLCInstitution | 9.99% | 266,756 | 13Gfiled Aug 3, 2026 ↗ |
RTW Fund Group GP, LLCStrategic | 9.97% | 266,307 | 13Gfiled Jul 30, 2026 ↗ |
Orbimed Advisors LLCInstitution | 9.97% | 266,306 | 13Dfiled Aug 5, 2026 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.